About 1,750 results

ALLMedicine™ Primary Myelofibrosis Center

Research & Reviews  623 results

ASXL1 mutations are prognostically significant in primary myelofibrosis, but not myelof...
Blood Advances; Guglielmelli P, Coltro G et. al.

Jan 13th, 2022 - ASXL1 mutations are prognostically significant in primary myelofibrosis, but not myelofibrosis following essential thrombocythemia or polycythemia vera.|2022|Guglielmelli P,Coltro G,Mannelli F,Rotunno G,Loscocco GG,|

Pathogenic "germline" variants associated with myeloproliferative disorders in apparent...
Clinical Genetics; Veitia RA, Innan H

Dec 28th, 2021 - Myeloproliferative syndromes (MPS) are hematologic malignancies due to the expansion of an abnormal hematopoietic stem cell. They include chronic myeloid leukemia (CML) and non-CML MPS such as polycythemia vera, essential thrombocythemia and prima...

Risk of mortality and second malignancies in primary myelofibrosis before and after rux...
Leukemia Research; Thomas JW, Jamy O et. al.

Dec 18th, 2021 - Primary myelofibrosis (PMF) is associated with morbidity and mortality. Ruxolitinib gained US FDA approval for treatment of intermediate/high-risk PMF in November 2011. We evaluated differences in survival and second primary malignancy (SPM) incid...

Myelofibrosis: genetic characteristics and the emerging therapeutic landscape.
Cancer Research; Tefferi A, Gangat N et. al.

Dec 17th, 2021 - Primary myelofibrosis (PMF) is one of three myeloproliferative neoplasms (MPN) that are morphologically and molecularly inter-related, the other two being polycythemia vera (PV) and essential thrombocythemia (ET). MPNs are characterized by JAK-STA...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  24 results

Optimizing PTCy Dose and Timing

Dec 9th, 2021 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Nov 10th, 2021 - Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that ...

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or...

Oct 28th, 2021 - This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose...

Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

Aug 24th, 2021 - This clinical trial is an open-label trial of ruxolitinib for the treatment of severe COVID-19 to assess its efficacy and safety. Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) is a well established, potent and selective inhibit...

see more →

News  50 results

Full-Dose Pacritinib Bests Ruxolitinib for Patients With Cytopenic Myelofibrosis

Dec 18th, 2021 - Most patients with myelofibrosis with moderate to severe thrombocytopenia treated with pacritinib were able to maintain full dose intensity over time and had numerically higher rates of symptom response vs those who received ruxolitinib (Jakafi). ...

Impact of Cytopenias on MF Treatment

Sep 7th, 2021 - Aaron Gerds, MD, MS: Allele burden is a concept in myelofibrosis. In general, MPNs [myeloproliferative neoplasms], where we look at the ratio of mutated reads in, say, a PCR [polymerase chain reaction] test vs nonmutated reads—it’s almost a rough ...

Overview of Primary Myelofibrosis

Aug 30th, 2021 - Srdan Verstovsek, MD, PhD: Primary myelofibrosis has different signs and symptoms, but the 3 classic ones are, No. 1, bone marrow failure that represents itself with anemia in particular. No. 1 is the anemia. The second one is the symptomatic sple...

Ruxolitinib for Myelofibrosis: Treatment Considerations

Aug 9th, 2021 - Pankit Vachhani, MD: In myelofibrosis, the JAK2 gene mutation occurs in about 50% to 60% of patients, the CALR gene mutation in about 25% to 30%, and MPO mutations in about 5% to 10%. In the remaining fraction of patients with myelofibrosis, about...

Ruxolitinib for Patients With Primary Myelofibrosis

Jul 14th, 2021 - Ruben Mesa, MD, FACP: We’re in an era in which there are the greatest number of phase 3 trials ever for myelofibrosis. It’s not even close, in terms of the amount of clinical investigations being done for these patients. I’m deeply excited about t...

see more →

Patient Education  2 results see all →